Ozoralizumab, a Humanized Anti-TNFα NANOBODY® Compound, Exhibits Efficacy Not Only at the Onset of Arthritis in a Human TNF Transgenic Mouse but Also During Secondary Failure of Administration of an Anti-TNFα IgG
Pharmacology, Toxicology and Pharmaceutical Science
3
5%
Agricultural and Biological Sciences
3
5%
Other
4
7%
Unknown
25
45%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 March 2024.
All research outputs
#3,186,002
of 26,419,306 outputs
Outputs from Frontiers in immunology
#3,393
of 33,180 outputs
Outputs of similar age
#72,017
of 458,515 outputs
Outputs of similar age from Frontiers in immunology
#174
of 1,700 outputs
Altmetric has tracked 26,419,306 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 33,180 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.6. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 458,515 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 1,700 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.
